The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

Sponsor
Taipei Veterans General Hospital, Taiwan
Study ID
NCT07073053
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Coronary Arterial Disease (CAD)
  • Glucagon-Like Peptide-1 Receptor Agonists
  • Type 2 Diabetes

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide 1.0 mg — DRUG
    add-on current standard treatment which includes SGLT2 inhibitor
  • Semaglutide 0.5 mg — DRUG
    add-on current standard treatment which includes SGLT2 inhibitor

Study Details

The investigators plan to enroll 60 patients from the outpatient clinics or inpatient wards of the Metabolism and Cardiology departments who, within the past three months, have undergone coronary angiography for the treatment of coronary artery disease, are currently using sodium-glucose cotransporter-2 (SGLT-2) inhibitors for glycemic control, and have not received glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy for more than three months. A randomized controlled clinical trial will be conducted, with 20 participants randomly assigned to receive semaglutide (a GLP-1 RA) at 1 mg once weekly for 6 months, another 20 participants to receive semaglutide at 0.5 mg once weekly for 6 months, and the control group (20 participants) to continue with standard treatment for 6 months. The effects after 6 months will be evaluated in terms of endothelial function, glycemic control indicators including glycemic variability assessed via continuous glucose monitoring (CGM), oxidative stress markers, and the incidence of symptomatic hypoglycemia. According to the treatment guidelines for type 2 diabetes, either GLP-1 receptor agonists or SGLT-2 inhibitors should be prioritized in patients with type 2 diabetes and coronary artery disease. Therefore, the medication choices in both the intervention and control groups in this study align with current treatment guidelines.

Key Dates

Start date
Oct 1, 2025
Status verified
Jul 2025
Primary completion
Jul 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: semaglutide 1.0mg weekly
    continue previous standard treatment with add-on semaglutide
  • Active Comparator: semaglutide 0.5mg weekly
    continue previous standard treatment with add-on semaglutide
  • No Intervention: control
    continue previous standard treatment

Primary Outcome Measure

change of Time-in-range (%) [ Time Frame: From enrollment to the end of treatment at 24 weeks ]

Central Contacts

Related Studies